Endocrine Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
|出版商||Mordor Intelligence Pvt Ltd||商品編碼||1005799|
|出版日期||內容資訊||英文 132 Pages
|全球內分泌檢測市場：COVID-19 的增長、趨勢、影響、預測（2021-2026） Endocrine Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)|
|出版日期: 2021年05月13日||內容資訊: 英文 132 Pages||
預計 2020 年內分泌檢測市場將增長至 9,170,620,000 美元，在 2021-2026 預測期內以 6.15% 的複合年增長率增長，到 2026 年將達到 13,119,510,000 美元。
在大流行期間，許多研究表明甲狀腺疾病患者容易感染 COVID-19，因此全球有多種甲狀腺激素水平需要檢查和控制。內分泌檢測非常需要。根據 2021 年 1 月的一項研究，50 名 COVID-19 患者的甲狀腺功能分析：回顧性研究，結果表明 COVID-19 越嚴重，TSH 和 TT3 水平越低。這表明具有顯著意義。 TSH和TT3水平的降低程度與疾病的嚴重程度呈正相關。因此，血清 TSH 和 TT3 水平的變化是 COVID-19 病程的重要標誌。
內分泌疾病的流行和診斷技術的進步主要推動了市場增長。此外，人口老齡化的加劇，加上全球對早期診斷和治療意識的增強，預計將推動市場增長。內分泌檢查測量內分泌腺分泌的激素水平，可參考肥胖、糖尿病、甲狀腺疾病等多種疾病的診斷。根據聯合國 2019 年的數據，成人糖尿病人數約為 4.36 億，預計到 2045 年將增加到 7 億。
根據世界衛生組織的數據，與 1975 年的水平相比，2016 年的肥胖患病率增加了兩倍。大約 19 億 18 歲以上的成年人超重。其中，約 6.5 億人肥胖。這些數字粗略地轉化為 39% 和 13% 的成年人超重和肥胖。 2019 年，約有 3800 萬 5 歲以下兒童超重或肥胖。此外，飲酒是各種內分泌失調和失調的最大危險因素之一。在全球範圍內，發達地區的高收入國家的酒精消費量最高。大量飲酒也是造成疾病負擔的主要因素之一。由於對內分泌檢測工具的高需求，市場參與者也關注產品開發和新品發佈。例如。 2018 年 10 月，DRG Diagnostics 推出了 Free T4 ELISA 檢測試劑盒，用於直接定量人血清中的游離甲狀腺素。
本報告調查了全球內分泌檢測市場，提供了市場概況、市場增長和障礙分析、市場機會、COVID-19 的影響以及按檢測、技術、最終用戶和地區劃分的市場規模. 它提供系統信息，例如趨勢和預測、競爭條件以及主要公司的簡介。
The endocrine testing market was valued at USD 9,170.62 million in 2020 and is expected to reach USD 13,119.51 million by 2026, registering a CAGR of 6.15% during the forecast period.
During the Pandemic, many research studies have been demonstrated that people with thyroid disorders are more prone to the COVID 19 infection, thus creating a significant demand for various endocrine tests globally in order to check and manage the thyroid hormone levels. As per the January 2021 research study titled "Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study" , the results of the study demonstrated that the more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance. The degree of the decreases in TSH and TT3 levels was positively correlated with the severity of the disease. Hence, the changes in serum TSH and TT3 levels are the important manifestations of the courses of COVID-19.
The growing prevalence of endocrine disorders and advancements in diagnostic technologies are primarily driving the market growth. Furthermore, the growing older population coupled with rising awareness about early diagnosis and treatment around the world is anticipated to boost the market growth. Endocrine testing refers to the measuring of levels of hormones secreted by the endocrine glands and diagnosis of various disorders such as obesity, diabetes, thyroid disease, and others. According to the International Federation in 2019, Diabetes approximately 463 million adults were living with diabetes and by 2045 it will rise to 700 million.
According to the World Health Organization, the prevalence of obesity had tripled in 2016, compared to the levels in 1975. About 1.9 billion adults, aged 18 years or above, were overweight. Of these, about 650 million were obese. These numbers roughly translate to 39% and 13% of the adults as overweight and obese, respectively. About 38 million children under the age of five were overweight or obese in 2019. In addition, alcohol consumption is one of the largest risk factors for various endocrine diseases and disabilities. Globally, high-income countries of the developed region have the highest alcohol consumption. This high consumption of alcohol is also serving as one of the major factors for the burden of the disease. Owing to the large demand for endocrine testing tools the market players are also focusing on product development and novel launches. For instance. in October 2018, DRG Diagnostics launched Free T4 ELISA test kits, The Free T4 ELISA Assay Kit is intended for the direct quantitative determination of free thyroxine in human serum.
The growing prevalence of diabetes, thyroid disorders in many of the countries around the globe is anticipated to further fuel the market growth. However, the high cost for the development of testing technologies is expected to impede market growth over the forecast period.
Thyroid Stimulating Hormone Testing (TSH) Anticipated to have Lucrative Growth
Thyroid-stimulating hormone (TSH) is produced by the pituitary gland and stimulates the thyroid gland to produce thyroxine and triiodothyronine which helps in metabolism. TSH testing used to measure thyroid level. The burden of thyroid disorders is increasing across the globe. For instance, as per the American Thyroid Association (ATA), an estimated 20 million Americans have some form of thyroid disease in 2019. It was estimated that more than 12 % of the U.S. population is anticipated to develop a thyroid condition during their lifetime. The major risk factors for thyroid-associated disorders are smoking, alcohol, and tobacco consumption. As per November 2019 study conducted by researchers from the Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, the results of the study demonstrated that Cigarette smoking is associated with a moderately higher level of FT4 and FT3, and lower TSH levels, which suggest partly opposing effects of alcohol consumption.
TSH measurement has recently gained a lot of importance in thyroid function testing mainly due to the technological developments in these tests facilitating cost-effective disease screening. TSH has also introduced new definitions of subclinical hypothyroidism or hyperthyroidism, along with delivering biochemical treatment targets. Furthermore, advancements in product technologies coupled with the growing affordability for healthcare is fueling the market growth. Mass spectroscopy is now used along with liquid chromatography for accurate results. This is believed to fuel market growth over the forecast period.
North America is Anticipated to Have Significant Share
North America is anticipated to have a significant share owing to the factors such as well-established healthcare infrastructure, high prevalence of obesity, advancements in diagnostic technologies, and new product launches. The less physical activity and growing prevalence of thyroid disorders are anticipated to fuel the market growth.
According to Health and Human Services (HHS), only less than 5% of adults participate in the 30 minutes of physical activity each day in the United States. More than 80% of adults do not meet the required guidelines for muscle strengthening and aerobic activities. This is leading to the consequences such as an imbalance of hormones due to obesity and diseases or conditions associated with the thyroid which is augmenting the demand for thyroid testing services. According to the American Cancer Society, it was estimated that about 44,280 new cases of thyroid cancer (12,150 in men and 32,130 in women) and about 2,200 deaths from thyroid cancer (1,050 men and 1,150 women) will be reported in the United States in 2021.
North America is likely to witness major growth in the coming years, owing to several initiatives, such as compulsory screening of newborns for congenital hypothyroidism, revolutionary research work on thyroid hormone function, cost-effective methods to detect thyroid cancer, promising research on Graves' disease, which is likely to further lead to improved prognosis, and new preventive treatments of thyroid diseases.
In mexico the growth is attributed to the rising prevalence of the disorders coupled with innovative product launches. For instance, in 2018, MedTech pioneer Proteomics International Laboratories Ltd launched of its world leading predictive diagnostic test for diabetic kidney disease, "PromarkerD" in Mexican Market. Hence, owing to the above-mentioned factors, the market studied is believed to grow over the forecast period in this region.
Global endocrine testing market is moderately competitive and there are several local as well as international companies in this market. Market players are focusing on new product launches, product innovations and geographical expansion. The key market players operating in the market include Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., bioMerieux SA, F. Hoffmann-La Roche Ltd and Siemens AG among others.